Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Miyuki Hayashi *Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0001-8098-3024
Amandeep Girdhar *Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Ying-Hui Ko *Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL, USA.
Kevin M KimDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0009-0008-0302-3685
Jacquelyn A DePierroDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Joseph R BuchlerDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Nikhita ArunprakashDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0009-0004-2708-1813
Aditya BajajDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Gino CingolaniDepartment of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL, USA. gcingola@uab.edu.ORCID 0000-0002-9206-9640
Lin GuoDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA. lin.guo@jefferson.edu.ORCID 0000-0002-2589-9513
Funding
Mechanism of Viral Genome Delivery into CellsR35GM140733 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CINGOLANI, GINO · 2021 to 2025
$2.8M
Elucidating the Mechanism in the Regulation of RNA-binding Protein Phase SeparationR35GM138109 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI Lin Guo · 2020 to 2026
$2.6M
Training Grant in Cellular, Biochemical and Molecular SciencesT32GM144302 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI DIANE E MERRY, PHILIP B WEDEGAERTNER · 2022 to 2026
$2.0M
Developing RNA Oligonucleotides to Mitigate Abberant FUS Phase Transition in FTD/ALSRF1NS121143 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI GUO, LIN · 2021 to 2021
$1.2M
Developing RNA Oligonucleotides to Mitigate Abberant FUS Phase Transition in FTD/ALSR01NS121143 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI GUO, LIN · 2024 to 2025
$741k
Protein therapeutics inspired by importinsR21NS128396 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CINGOLANI, GINO · 2022 to 2022
$429k
NIGMS NIH HHS R35 GM138109NIGMS NIH HHS R35 GM140733NIGMS NIH HHS T32 GM144302NINDS NIH HHS R01 NS121143NINDS NIH HHS R21 NS128396NINDS NIH HHS RF1 NS121143U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM138109U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM140733U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R21NS128396U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) RF1NS121143
6 · The paper itself
Abstract
Importin β-superfamily nuclear import receptors (NIRs) mitigate mislocalization and aggregation of RNA-binding proteins (RBPs), like FUS and TDP-43, which are implicated in neurodegenerative diseases. NIRs potently disaggregate RBPs by recognizing their nuclear localization signal (NLS). However, disease-causing mutations in NLS compromise NIR binding and activity. Here, we define features that characterize the anti-aggregation activity of NIR and NLS. We find that high binding affinity between NIR and NLS, and optimal NLS location relative to the aggregating domain plays a role in determining NIR disaggregation activity. A designed FUS chimera (FUS
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Engineered NLS-chimera downregulates expression of aggregation-prone endogenous FUS. · full record | OpenQuestion